Efficacy of Ultra-Low dose Valganciclovir Chemoprophylaxis for Cytomegalovirus infection in ABO Incompatible Kidney Transplantation Recipients

Cytomegalovirus (CMV) infection can increase morbidity and mortality in kidney transplant(KTP) patients. Chemoprophylaxis with valganciclovir (VGCV) is recommended for ABO incompatible(ABOi) KTP as it significantly reducesCMV disease and infection. The recommended dose of VGCV for prevention of CMV in a KTP recipient is 900 mg once daily and the treatment duration is 6 months. However, it is expensive due to which sufficient amounts might not be administered.

Source: Transplantation Proceedings - April 11, 2018 Category: Transplant Surgery Authors: Jin Ho Lee, Seun Deuk Hwang, Joon Ho Song, Jeong Ho Kim, Hee Yeoun Kim, Dong Yeol Lee, Joon Seok Oh, Yong Hun Sin, Joong Kyung Kim Source Type: research